A clinical case of complex EGFRMUT treatment of NSCLC using targeted therapy with Osimertinib
https://doi.org/10.62546/3034-1477-2025-3-2-25-30
Abstract
Lung cancer is the most common malignant neoplasm and ranks first in the structure of cancer mortality. Lung cancer has long been thought to be a smoker’s disease and largely preventable by limiting tobacco use, but recent studies have shown an alarming increase in the incidence of the disease among non-smokers of both sexes. Personalized medicine, including careful molecular genetic testing, optimizes treatment for each patient and improves their quality of life during therapy.
The subject of this article is a specific clinical case of the effective use of Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), which has been widely used as first-line therapy in patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC), and currently shows excellent results in the adjuvant mode. The aim of the work is to analyze the effectiveness of the use of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in lung adenocarcinoma using an example from clinical practice. During the discussion of the specifics of treatment of a patient with NSCLC, the results of laboratory tests, data from various diagnostic and treatment methods are used.
About the Authors
E. V. Markarova
Moscow Research Clinical Institute named after M. F. Vladimirsky (MONIKI)
Russian Federation
Russian Federation
Ekaterina V. Markarova
Shchepkina st., 61/2, Moscow, 129090
L. M. Kogonia
Moscow Research Clinical Institute named after M. F. Vladimirsky (MONIKI)
Russian Federation
Russian Federation
Lali M. Kogonia
Shchepkina st., 61/2, Moscow, 129090
References
1. Thai А.А., Solomon B.J., Sequist L.V. Lung cancer // Lancet. 2021. Vol. 398, No. 10299. Р. 535–554. doi: 10.1016/s0140-6736(21)00312-3.
2. International Agency for Research on Cancer. Global Cancer Observatory: Cancer Today. Lyon: World Health Organization, 2020.https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf.
3. Sheehan D.F., Criss S.D., Chen Y. et al. Lung cancer treatment costs by treatment strategy and stage of therapy in Medicare-insured patients // Cancer Med. 2019. Vol. 8, No. 1. Р. 94–103. doi: 10.1002/cam4.1896.
4. Bernie D., Ferley J., Boniol M. et al. Cancer incidence across five continents. Vol. 160. Lyon: IARC Sci Publ. 2008. Vol. IX. Р. 1–837.
5. Da Cunha Santos G, Shepherd FA, Cao MS. EGFR mutations and lung cancer // Ann. Rev. Pathol. 2011. Vol. 6. Р. 49–69. doi: 10.1146/annurev-pathol-011110-130206.
6. Riley G.J., Yu H.A. EGFR: a paradigm for oncogenic lung cancer // Clin. Cancer Res. 2015. Vol. 21, No. 10. Р. 2221– 2226. doi: 10.1158/1078-0432.CCR-14-3154.
7. Lynch T.J., Bell D.W., Sordella R. et al. Activating mutations in epidermal growth factor receptor underlie gefitinib sensitivity of non-small cell lung cancer // N. Engl. J. Med. 2004. Vol. 350, No. 21. Р. 2129–2139. doi: 10.1056/NEJMoa040938.
8. Yamane H., Ochi N., Yasugi M. et al. Docetaxel for early-stage non-small cell lung cancer bearing the EGFR T790M activating mutation // Onco Targets Ther. 2013. Vol. 6. Р. 155–160. doi: 10.2147/OTT.S41797.
9. Markarova E.V., Stashuk G.A. Clinical experience with the use of afatinib in non-small cell lung cancer II line therapy. Practical oncology, 2020, Vol. 21, No. 1, рp. 64–74 (In Russ.).
10. Kogoniya L.M., Markarova E.V., Stashuk G.A. et al. Clinical experience of effective use of palliative targeted therapy in a patient with EGFR-negative lung adenocarcinoma. Medical Council, 2019, No. 10, pp. 142–145 (In Russ.).
11. Markarova E.V., Kogoniya L.M., Stashuk G.A. et al. Efficacy of afatinib in the 3rd line of therapy for lung adenocarcinoma with EGFR mutation in an 82-year-old patient. Russian Journal of Biotherapeutics, 2018, Vol. 17, No. S, рр. 44 (In Russ.).
12. Sun S., Xu S., Yang Z. et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014 to present) // Expert Opin. Ther. Pat. 2021. Vol. 31, No. 3. Р. 223–238. doi: 10.1080/13543776.2021.1860210.
13. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 7.2019 (2019). Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (In Russ.).
14. O’Kane G.M., Bradbury P.A., Feld R. и др. Необычные мутации гена рецептора эпидермального фактора роста при распространенном немелкоклеточном раке легкого Uncommon EGFR mutations in advanced non-small cell lung cancer // Lung Cancer. 2017. Vol. 109. Р. 137–144. doi: 10.1016/j.lungcan.2017.04.016.
15. Thress K.S., Paweletz Cl.P., Felip E.et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in nonsmall cell lung cancer harboring EGFR T790M // Nat. Med. 2015. Vol. 21, No. 6. Р. 560–562. doi: 10.1038/nm.3854.
16. Oxnard G.R., Hu Yu., Mileham K.F. et al. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib // JAMA Oncol. 2018. Vol. 4, No. 11. Р. 1527–1534. doi: 10.1001/jamaoncol.2018.2969.
17. Niederst M.J., Hu Н., Mulvey Н.Е. et al. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies // Clin. Cancer Res. 2015. Vol. 21, No. 17. Р. 3924–3933. doi: 10.1158/1078-0432.CCR-15-0560.
18. Лактионов К.К., Артамонова Е.В., Бредер В.В. и соавт. Немелкоклеточный рак легкого. Практические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли 2024; 14 (3s2): 65–105.
Review
For citations:
Markarova E.V., Kogonia L.M. A clinical case of complex EGFRMUT treatment of NSCLC using targeted therapy with Osimertinib. Clinical Case in Oncology. 2025;3(2):25-30. (In Russ.) https://doi.org/10.62546/3034-1477-2025-3-2-25-30
Views:
7
Email this article 